Innovax-ILT Formulation:   Each dose contains:   Recombinant Marek's Disease Virus (HVT FC-126 Strain......... > 2248 PFU Infectious Laryngotracheitis Virus (D and I Glycoprotein, 138 Strain) PFU - Plaque Forming Unit Suspension for Injection   (In-Ovo/SC) Philippin - Tiếng Anh - FDA (Food And Drug Administration)

innovax-ilt formulation: each dose contains: recombinant marek's disease virus (hvt fc-126 strain......... > 2248 pfu infectious laryngotracheitis virus (d and i glycoprotein, 138 strain) pfu - plaque forming unit suspension for injection (in-ovo/sc)

msd animal health (phils.), inc.; distributor: n.a. - live recombinant marek's disease (md) virus , infectious laryngotracheitis (ilt) virus vaccine (vet.) - suspension for injection (in-ovo/sc) - formulation: each dose contains: recombinant marek's disease virus (hvt fc-126 strain......... > 2248 pfu infectious laryngotracheitis virus (d and i glycoprotein, 138 strain) pfu - plaque forming unit

Purevax Felv 1 dose of 1mL or 0.5 mL contains FeLV recombinant Canarypoxvirus (vCP97-10˄7.2CCID50 Suspension For Injection (Sc) Philippin - Tiếng Anh - FDA (Food And Drug Administration)

purevax felv 1 dose of 1ml or 0.5 ml contains felv recombinant canarypoxvirus (vcp97-10˄7.2ccid50 suspension for injection (sc)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - feline leukemia of felv recombinant canarypox virus vaccine (vcp97) - suspension for injection (sc) - 1 dose of 1ml or 0.5 ml contains felv recombinant canarypoxvirus (vcp97-10˄7.2ccid50

Vaxxitek HVT + IBD + ND Formulation:  Each dose contains:  Marek's Disease Virus, Serotype 3, VHVT310 (Recombinant HVT, FC-126 Strain) ............... >5696 pfu Infectious Bursal Disease Viral Protein 2 Newcastle Disease Virus Fusion (F) Protein, Genotype VIID PFU - Plaque Forming Unit Suspension for Injection  (In-Ovo/SC) Philippin - Tiếng Anh - FDA (Food And Drug Administration)

vaxxitek hvt + ibd + nd formulation: each dose contains: marek's disease virus, serotype 3, vhvt310 (recombinant hvt, fc-126 strain) ............... >5696 pfu infectious bursal disease viral protein 2 newcastle disease virus fusion (f) protein, genotype viid pfu - plaque forming unit suspension for injection (in-ovo/sc)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - live recombinant marek's disease (md) virus , infectious bursal disease (ibd) virus , newcastle disease (nd) virus vaccine (vet.) - suspension for injection (in-ovo/sc) - formulation: each dose contains: marek's disease virus, serotype 3, vhvt310 (recombinant hvt, fc-126 strain) ............... >5696 pfu infectious bursal disease viral protein 2 newcastle disease virus fusion (f) protein, genotype viid pfu - plaque forming unit

SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen vaccine 50 micrograms powder vial and suspension vial for suspension for injection Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

shingrix recombinant varicella zoster virus glycoprotein e antigen vaccine 50 micrograms powder vial and suspension vial for suspension for injection

glaxosmithkline australia pty ltd - recombinant varicella zoster virus glycoprotein e antigen, quantity: 50 microgram - injection, powder for - excipient ingredients: sucrose; monobasic sodium phosphate dihydrate; dibasic potassium phosphate; polysorbate 80 - shingrix is indicated for the prevention of herpes zoster (hz) and post-herpetic neuralgia in: - adults 50 years of age or older; - adults 18 years of age or older at increased risk of hz.